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Abstract
Background: Doxorubicin is currently the most effective chemotherapeutic drug used to treat breast cancer. It has,
however, been shown that doxorubicin can induce drug resistance resulting in poor patient prognosis and survival.
Studies reported that the interaction between signalling pathways can promote drug resistance through the
induction of proliferation, cell cycle progression and prevention of apoptosis. The aim of this study was therefore to
determine the effects of doxorubicin on apoptosis signalling, autophagy, the mitogen-activated protein kinase
(MAPK)- and phosphoinositide 3-kinase (PI3K)/Akt signalling pathway, cell cycle control, and regulators of the
epithelial-mesenchymal transition (EMT) process in murine breast cancer tumours.
Methods: A tumour-bearing mouse model was established by injecting murine E0771 breast cancer cells,
suspended in Hank’s Balances Salt Solution and Corning® Matrigel® Basement Membrane Matrix, into female C57BL/
6 mice. Fourty-seven mice were randomly divided into three groups, namely tumour control (received Hank’s
Balances Salt Solution), low dose doxorubicin (received total of 6 mg/ml doxorubicin) and high dose doxorubicin
(received total of 15 mg/ml doxorubicin) groups. A higher tumour growth rate was, however, observed in
doxorubicin-treated mice compared to the untreated controls. We therefore compared the expression levels of
markers involved in cell death and survival signalling pathways, by means of western blotting and fluorescence-
based immunohistochemistry.
Results: Doxorubicin failed to induce cell death, by means of apoptosis or autophagy, and cell cycle arrest,
indicating the occurrence of drug resistance and uncontrolled proliferation. Activation of the MAPK/ extracellular-
signal-regulated kinase (ERK) pathway contributed to the resistance observed in treated mice, while no significant
changes were found with the PI3K/Akt pathway and other MAPK pathways. Significant changes were also observed
in cell cycle p21 and DNA replication minichromosome maintenance 2 proteins. No significant changes in EMT
markers were observed after doxorubicin treatment.
Conclusions: Our results suggest that doxorubicin-induced drug resistance and tumour growth can occur through
the adaptive role of the MAPK/ERK pathway in an effort to protect tumour cells. Previous studies have shown that
the efficacy of doxorubicin can be improved by inhibition of the ERK signalling pathway and thereby treatment
failure can be overcome.
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Background
Cancer is a major disease burden worldwide and the
occurrence of cancer is expected to increase due to the
increasing prevalence of lifestyle risk factors and the
growth and aging of the population [1]. Based on Global
Cancer Incidence, Mortality and Prevalence (GLOBO-
CAN) estimates, breast cancer was the most frequently
diagnosed cancer and the leading cause of cancer deaths
among females in 2012 worldwide [1]. Although signifi-
cant progress has been made regarding treatment
options for cancer patients, therapeutic resistance and
toxicity of these drugs to normal tissue still remains a
major problem. Resistance to chemotherapeutic drugs
can cause treatment failure in over 90% of patients with
metastatic cancer [2].
Doxorubicin (DXR) is part of the anthracycline family
and is currently the most effective chemotherapeutic
drug used to treat breast cancer [3, 4]. It has, however,
been shown that DXR can induce drug resistance and
even tumour growth resulting in poor patient prognosis
and survival [5–7]. Although several mechanisms have
been investigated, DXR resistance still remains a major
unresolved issue in the treatment of cancer patients [8].
Studies reported that the interaction between signalling
pathways can promote DXR resistance through the
induction of proliferation, cell cycle progression and
prevention of apoptosis [5, 9, 10].
The mitogen-activated protein kinase (MAPK)/ extra-
cellular-signal-regulated kinase (ERK) and phosphoinosi-
tide 3-kinase (PI3K)/Akt pathways play an essential role in
the regulation of proliferation, cell cycle progression, and
apoptosis [9, 11]. The MAPK/ERK pathway has been
shown to promote DXR resistance through its adaptive
role in protecting cancer cells from oxidative stress [12].
Reactive oxygen species (ROS) generation following DXR
treatment can also activate other MAPK pathways, includ-
ing the c-jun N-terminal kinases (JNK) and p38 pathways
[12]. The PI3K/Akt pathway can also induce chemo-resist-
ance and promote tumorigenesis by phosphorylating vari-
ous downstream substrates involved in cell survival, cell
cycle, cell metabolism, gene transcription and protein syn-
thesis [13].
In addition to the mechanism of DXR to induce apop-
tosis, DXR-mediated DNA damage can also induce cell
cycle arrest [14]. This can occur through the activation
of the tumour suppressor p53, which regulates the tran-
scription of various genes, including p21 and p16, that
are involved in cell cycle control, DNA repair and
apoptosis [14, 15]. Defects in these regulators can lead
to the failure of DXR to induce cell cycle arrest and
thereby promote DXR resistance [16, 17].
Besides the effects of proliferation markers and cell cycle
regulators on drug resistance, the epithelial-mesenchymal
transition (EMT) process has also been shown to play a
role in drug resistance by inhibiting apoptosis and pre-
venting senescence [18]. Biomarkers of the EMT process
include the cell surface protein, E-cadherin, cytoskeletal
proteins, such as alpha smooth muscle actin (α-SMA) and
Vimentin, and the transcription factor, Snail [19]. This
process can be activated by the MAPK/ERK and PI3K/Akt
signalling pathways, which further emphasises the inter-
action between various pathways and drug resistance [20].
Another process that can be involved in drug resist-
ance is autophagy [21, 22]. Autophagy, also known as
macroautophagy, plays a role in maintaining intracellular
homeostasis and survival by degrading damaged proteins
and organelles and recycling their components to regen-
erate metabolic precursors [21]. It has been shown that
autophagy can drive cancer cells to acquired chemo-re-
sistance by preventing cellular damage and protecting
cancer cells against apoptosis [10, 23]. However, when
autophagy is induced by excessive cellular stress it can
lead to the upregulation of apoptosis and autophagy
dependent cell death (ADCD) [10, 23].
Elucidating the mechanism by which these pathways
promote drug resistance can improve the efficacy of che-
motherapeutic drugs and overcome treatment failure.
The aim of this study was therefore to determine the ef-
fects of doxorubicin on apoptosis signalling, autophagy,
the MAPK- and PI3K/Akt signalling pathway, cell cycle
control and regulators of the EMT process in murine
breast cancer tumours. We compared the expression
levels of markers involved in cell death and survival
signalling pathways, by means of western blotting and
fluorescence-based immunohistochemistry, in the breast
tumours of mice treated with low and high doses of
doxorubicin. Our results suggest that DXR-induced drug
resistance and tumour growth can occur through the
adaptive role of the MAPK/ERK pathway in an effort to
protect tumour cells. Previous studies have shown that
the efficacy of doxorubicin can be improved by
inhibition of the ERK signalling pathway and thereby
treatment failure can be overcome [6, 24–26].
Methods
Animal model
Ethical clearance was obtained from the Stellenbosch
University Ethical Committee (no. SU-ACUM13–00027).
Six-week old female wildtype C57BL/6 mice were
obtained from the Tygerberg animal facility. The mice
were kept under temperature controlled conditions,
underwent a reverse dark-light cycle and were provided
standard mouse pellets and tap-water ad libitum in
individually ventilated cages (IVC) with autoclaved
bedding at the Stellenbosch University animal facility.
Murine E0771 breast cancer cells, syngeneic to C57BL/6
mice, suspended in Hank’s Balances Salt Solution (HBSS,
Sigma-Aldrich, MO, USA) were added to Corning®
Christowitz et al. BMC Cancer          (2019) 19:757 Page 2 of 10
Matrigel® Basement Membrane Matrix (9.2mg/ml
protein, BD Bio-sciences, CA, USA) in a 1:1 ratio. When
the mice reached an age of 10 weeks (21.9 g ± 0.25 g),
100 μl was injected subcutaneously at the fourth mam-
mary fat pad of the mice to initiate tumour growth.
Tumour growth was monitored every second day and
length and width measurements were taken to calculate
tumour volume (mm3) with the following equation:
(length x width2)/2.
DXR treatment were initiated once the tumours were
palpable (between day 6 and day 9). Forty-seven mice
were randomly divided into three groups, namely TC
(n = 15), LD-DXR (n = 16) and HD-DXR (n = 16) groups.
The sample size were based on previously unpublished
studies. Three doses of DXR were administered three
days apart by means of intraperitoneal injection. The TC
group received HBSS, the LD-DXR group received 2
mg/kg DXR (total of 6 mg/kg) and the HD-DXR group
received 5 mg/kg DXR (total of 15 mg/kg). The dosages
were based on previously unpublished studies.
The endpoint of the study was reached when the tu-
mours reached a volume of 400mm3. Mice were anaes-
thetised with Isofluorane (Isofor, Safeline Pharmaceuticals,
RSA) before exsanguination. The tumours were then
excised and cut into two parts to be used for western
blotting and immunohistochemistry. The samples used
for western blotting were snap-frozen in liquid nitrogen
and stored at − 80 °C. The samples used for immunohisto-
chemistry were mounted with tissue freezing medium
(Leica Biosystems, Germany, UK) and frozen in ice-cold
isopentane and stored at − 80 °C.
Western blots
Standard Radioimmunoprecipitation assay (RIPA) buffer
was used to harvest protein lysates from tumour tissues
while a Bradford assay was performed to determine pro-
tein concentration. Protein samples (50 μg), prepared
with Laemmli’s sample buffer, were loaded onto 4–20%
Criterion™ TGX Stain-Free™ Precast Gels (BioRad, CA,
USA). Proteins were separated at 100 V for 10min and
120 V for 60min in Tris/Glycine/SDS running buffer
(BioRad, CA, USA). Proteins were transferred onto
Polyvinylidene difluoride (PVDF) membranes (Trans-Blot®
Turbo RTA Midi PVDF transfer kit, BioRad, CA, USA)
with the Trans-Blot® Turbo Transfer System (BioRad, CA,
USA) with the conditions of 25 V, 1.0A, 30min. The
Stain-Free™ properties of the membranes were utilized on
the Chemidoc™ MP System (BioRad, CA, USA) to deter-
mine the total protein intensities of each membrane.
Membranes were blocked in 5% milk for 1 h and incu-
bated in primary antibody, prepared in tris-buffered saline
with tween 20 (TBS-T), at 4 °C overnight. On the follow-
ing day membranes were incubated in secondary antibody,
prepared in TBS-T, for 1 h at RT. Antibody details are
listed in the Additional file 1. After incubation, mem-
branes were developed on the ChemiDoc™ MP System
with Clarity™ Electrochemiluminescence (ECL) Substrate
(BioRad, CA, USA).
Fluorescence-based immunohistochemistry
Tumour tissues were sectioned into 8 μm sections with
a Leica CM110 Cryostat (Leica Biosystems, Germany,
UK). The sections were fixed in 100% ice-cold methanol
for 5 min and blocked in 2.5% goat serum, prepared in
phosphate-buffered saline (PBS), for 1 h. Sections were
covered with p-ERK primary antibody, prepared in PBS,
and incubated at 4 °C overnight or with p21 primary
antibody, prepared in 2.5% goat serum, and incubated
for 1 h at RT. The sections for the secondary antibody
control were covered in PBS. On the following day sec-
tions were covered in fluorescein isothiocyanate (FITC)
secondary antibody, prepared in PBS or 2.5% goat
serum, and incubated for 1 h at RT. Antibody details are
listed in the Additional file 1. The sections were stained
with 10 μg/ml Hoechst 33342 (Sigma-Aldrich, MO,
USA), prepared in PBS (1:200), for 15 min at RT.
Coverslips were mounted onto the slides with Dako
Fluorescence Mounting Medium (Agilent Technologies,
CA, USA). Slides were protected from light and stored
at − 20 °C until imaging. Five images per section were
obtained with the Nikon NIS-Element BR v4.10.00 im-
aging software on the Nikon Eclipse E400 microscope
using the 40x objective. The 405 nm and 488 nm
excitation lasers for Hoechst and FITC, detected in the
emission ranges of 450–490 nm and 520–540 nm,
respectively, were used.
Statistical analyses
An analysis of covariance (ANCOVA) (p < 0.05) was per-
formed to compare the tumour volume between the TC
(n = 15), LD-DXR (n = 16) and HD-DXR (n = 16) groups.
The western blot experiments were conducted with
technical repeats of n = 2 and biological repeats of n = 8.
Bio-Rad Image Lab™ software v5.1 was used for
normalization of the protein specific intensities against
total protein intensities. Results were analysed in
GraphPad Prism v7.0 by performing a one-way analysis
of variance (ANOVA) with Bonferonni post hoc test
(p < 0.05). The mean values ± standard error of the mean
was reported. The fluorescent-based immunohistochem-
istry experiments were conducted with biological repeats
of n = 8. Five images per section were analysed in Image
J software v1.52a. The following equation was used to
calculate the corrected total cryosection fluorescence:
mean of integrated density – (mean of area of selected
cell x mean fluorescence of background readings).
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Results
Higher tumour growth rate was observed after DXR
treatment
A tumour-bearing mouse model was established by
injecting murine breast cancer cells, suspended in
Corning® Matrigel®, into female mice. When the tumours
were palpable, the mice either received a vehicle
treatment, a low dose of DXR or a high dose of DXR
treatment. The tumours grew rapidly over the study
period and showed resistance to both DXR doses.
Analyses revealed that both low dose (LD)-DXR and
high dose (HD)-DXR groups has a significantly increased
tumour volume when compared to the tumour control
(TC) group (Fig. 1). No significant differences in tumour
volume were observed between the LD-DXR and HD-
DXR groups (Fig. 1).
Inability of DXR to induce apoptosis or autophagy,
indicating the occurrence of DXR resistance
To determine whether apoptosis was induced after DXR
treatment, western blot experiments were performed to
compare the protein expression levels of different
apoptotic markers, including B-cell lymphoma 2 (Bcl-2),
caspase (Casp)-9, Casp-8, Casp-3 and Casp-7 between
the different groups. c-Casp 7 protein expression de-
creased significantly in tumour-bearing mice treated
with a low dose of DXR, whereas a non-significant
decrease was observed in mice treated with a high dose
of DXR (Fig. 2a). No significant differences in the other
apoptotic markers were observed between the different
groups. Bcl-2 protein expression showed a slight
decrease in the LD-DXR and HD-DXR groups compared
to the TC group (Fig. 2a). Casp-8 showed a greater de-
crease in protein expression levels after DXR treatment,
than Casp-9 (Fig. 2a). The ratio between cleaved Casp-3
and Casp-3 showed a decrease in both treatment groups
compared to the control, with the LD-DXR group show-
ing the lowest protein expression (results not shown).
To determine whether autophagy was induced after
DXR treatment, western blot experiments were
performed to compare the protein expression levels of
markers, p62 and microtubule-associated protein light
chain 3 (LC3)-I/−II, between the TC, LD-DXR and HD-
DXR groups. No significant differences were again
observed between the different groups (Fig. 2b).
The MAPK/ERK pathway had a greater effect on DXR
resistance than the PI3K/Akt pathway and other MAPK
pathways
To determine the effects of the MAPK/ERK signalling
pathway on DXR resistance, we performed western blot
experiments to compare the protein expression levels of
markers, platelet-derived growth factor receptor alpha
(PDGFRα), c-Raf and ERK, between the different groups.
We also assessed other MAPK pathways, including the
p38 and JNK pathways. PDGFRα protein expression in-
creased significantly in tumour-bearing mice treated
with a low dose of DXR, whereas a non-significant in-
crease was observed in mice treated with a high dose of
DXR (Fig. 3a). The ratio between phosphorylated ERK
(p-ERK) and total ERK showed a gradual increase in
protein expression levels as the dosage of DXR
increased, with the HD-DXR group showing a significant
increase compared to the TC group (Fig. 3a). Fluores-
cence-based immunohistochemistry was performed to
support the western blot results of p-ERK. However,
no significant differences in p-ERK signal was ob-
served between the different groups (Fig. 3c). No sig-
nificant differences were observed in the protein
expression levels of c-Raf, p38 and JNK between the
different groups (Fig. 3a). To determine the effects of
the PI3K/Akt/mammalian target of rapamycin
Fig. 1 Effects of DXR treatment on the average tumour volume (mm3). DXR treatment were initiated between day 6 and day 9. Three doses of
DXR were administered three days apart. Error bars indicate the standard error of the mean (n = 15 (TC group), n = 16 (LD-DXR and HD-DXR
groups)). The slope of the regression lines from the LD-DXR and HD-DXR groups were significantly different compared to the TC group. [31]
Christowitz et al. BMC Cancer          (2019) 19:757 Page 4 of 10
(mTOR) pathway on DXR resistance, western blot
experiments were performed to compare the protein
expression level of markers, phosphatase and tensin
homolog (PTEN), PI3Kp85, phosphoinositide-
dependent kinase-1 (PDK1), Akt and mTOR, between
the different groups. There were, however, no signifi-
cant differences in protein expression observed
between the different groups (Fig. 3b).
Changes observed in cell cycle regulators after DXR
treatment
Western blot experiments were performed to compare
the protein expression levels of different markers in-
volved in the cell cycle and DNA replication between
the TC, LD-DXR and HD-DXR groups. These markers
included the tumour suppressor p53, cyclin-dependent
kinase (CDK) inhibitors, p21 and p16, and the prolifera-
tion marker, minichromosome maintenance 2 (MCM2).
A significant reduction in p21 expression was observed
in the LD-DXR group compared to the TC group, while
a non-significant reduction in p21 expression was ob-
served in the HD-DXR group (Fig. 4a). Fluorescence-
based immunohistochemistry was performed to support
the western blot results of p21 qualitatively (Fig. 4b).
Cytoplasmic signal of inactive p21 was also observed in
the LD-DXR and HD-DXR groups (Fig. 4b). MCM2 pro-
tein expression increased significantly in both treatment
groups compared to the control group (Fig. 4a). No sig-
nificant differences were observed in the protein expres-
sion levels of p53 and p16 between the different groups
(Fig. 4a).
EMT did not occur during DXR-induced drug resistance
and tumour growth
Western blot experiments were performed to compare the
protein expression levels of the EMT markers, α-SMA, E-
cadherin, Snail and Vimentin, between the TC, LD-DXR
and HD-DXR groups. No significant differences were
however observed between the different groups (Fig. 5).
Discussion
DXR can induce drug resistance and even tumour
growth resulting in poor patient prognosis and survival
[5–7]. Although several mechanisms have been investi-
gated, DXR resistance still remains a major unresolved
issue in the treatment of cancer patients [8]. Studies
have shown that the interaction between signalling path-
ways can promote drug resistance through the induction
of proliferation, cell cycle progression and prevention of
apoptosis [5, 9, 10].
The aim of this study was therefore to determine the
effects of doxorubicin on apoptosis signalling, autoph-
agy, the MAPK- and PI3K/Akt signalling pathway, cell
cycle control, and regulators of the EMT process in
murine breast cancer tumours. We compared the
expression levels of markers involved in cell death and
survival signalling pathways, by means of western
blotting and fluorescence-based immunohistochemistry,
in the breast tumours of mice treated with low and high
doses of doxorubicin.
To determine whether cell death was induced after
DXR treatment we assessed the expression levels of
different markers involved in apoptosis and autophagy.
A significant decrease in c-Casp 7 protein expression
Fig. 2 a Protein expression of c-Casp 7 between the TC, LD-DXR and HD-DXR groups (n = 8). * - significantly different compared to TC group
(p < 0.05). Representative images of Bcl-2, Casp 9, c-Casp 8, Casp 8, c-Casp 3 and Casp 3 protein expression between the TC, LD-DXR and HD-DXR
groups (n = 8). b Representative images of p62 and LC3-I/−II protein expression between the TC, LD-DXR and HD-DXR groups (n = 8)
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was observed in tumour-bearing mice treated with a low
dose of DXR, whereas a non-significant decrease was
observed in mice treated with a high dose of DXR
(Fig. 2a). An increase in p62 protein expression was
observed in the HD-DXR group, however, not significant
(Fig. 2b). No significant changes in LC3 protein expression
was observed after DXR treatment (Fig. 2b). We therefore
showed that DXR failed to induce cell death through
apoptosis or ADCD, indicating the occurrence of drug
resistance. It is well known that chemo-resistance is
associated with the inability of chemotherapeutic drugs to
induce cell death [10, 23].
Fig. 3 a Protein expression of PDGFRα and p-ERK/ERK between the TC, LD-DXR and HD-DXR groups (n = 8). * - significantly different compared
to TC group (p < 0.05). Representative images of p-cRaf, cRaf, p-p38, p38, p-JNK and JNK protein expressions between the TC, LD-DXR and HD-
DXR groups (n = 8). b Representative images of p-PTEN, PTEN, p-PI3Kp85, PI3Kp85, p-PDK1, PDK1, p-Akt thr308, p-Akt ser473, Akt, p-mTOR and
mTOR protein expressions between the TC, LD-DXR and HD-DXR groups (n = 8). c Representative images of p-ERK-FITC signal in tumour tissues
following DXR treatment (n = 8). Hoechst 33342 – nuclei; FITC – p-ERK; solid arrows – localised areas of intense signal in cytoplasm; scale = 20 μm,
40x objective
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Interactions between MAPK/ERK and PI3K/Akt sig-
nalling pathways play an essential role in the regula-
tion of proliferation, cell cycle progression and
apoptosis [9, 11]. The mechanisms by which the
MAPK/ERK and PI3K/Akt signalling pathways regu-
late DXR-induced cell death and drug resistance are,
however, controversial [5]. Some studies have shown
that sustained ERK activation contributes to DXR-in-
duced cell death and can be negatively regulated by
the PI3K/Akt pathway [5, 6].
In contrast, other studies have reported that ERK
activation can protect cells from DXR-induced cell death
[6, 12]. The MAPK/ERK pathway has been shown to
promote DXR resistance through its adaptive role in pro-
tecting cells from oxidative stress [12]. ROS generation
following DXR treatment can activate PDGFRα, thereby
increasing the activation of the MAPK/ERK pathway as
well as other MAPK pathways, including the JNK and p38
pathways [12].
A study done by Jin et al. showed that the PI3K/Akt
pathway had a greater effect on chemo-resistance than
the MAPK pathway in breast cancer cells [27]. We
assessed the expression levels of markers associated with
the MAPK pathway, such as PDGFRα, cRaf, ERK, p38
Fig. 4 a Protein expression of p21 and MCM2 between the TC, LD-DXR and HD-DXR groups (n = 8). * - significantly different compared to TC group
(p < 0.05). Representative images of p16 and p53 protein expressions between the TC, LD-DXR and HD-DXR groups (n = 8). b Representative images of
p21-FITC signal and localisation in tumour tissues following DXR treatment (n = 8). Hoechst 33342 – nuclei; FITC – p21; solid arrows – localised areas of
intense signal in nuclei; dashed arrows- localised areas of intense signal in cytoplasm; scale = 20 μm, 40x objective
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and JNK, and markers associated with the PI3K/Akt
pathway, such as PTEN, PI3Kp85, PDK1, Akt, and
mTOR, to determine which pathway was responsible for
DXR-induced drug resistance and tumour growth in the
tumour-bearing mouse model. We observed increased
protein expression for both PDGFRα and p-ERK and no
significant changes in markers of the PI3K/Akt pathway
and other MAPK pathways, indicating that the MAPK/
ERK pathway had a greater effect on DXR resistance
(Fig. 3).
In addition to the mechanism of DXR to induce
apoptosis, DXR-mediated DNA damage can also in-
duce cell cycle arrest [14]. This can occur through
the activation of the tumour suppressor p53, which
regulates the transcription of various genes involved
in cell cycle control, DNA repair and apoptosis [14].
CDK inhibitors, such as p21 and p16, are major
targets of p53 and is known to function as mediators
of DXR-induced cell cycle arrest [14–17].
We therefore assessed the expression level of different
cell cycle regulators, such as p53, p21 and p16, to deter-
mine whether DXR was able to induce cell cycle arrest.
A significant reduction in p21 expression was observed
in the LD-DXR group compared to the TC group, while
a non-significant reduction in p21 expression was ob-
served in the HD-DXR group (Fig. 4a). p21 is an inhibitor
of CDKs and activation of this protein can induce cell
cycle arrest. Downregulation of this protein may therefore
indicate that DXR was unable to induce cell cycle arrest.
Hwang et al. showed that sustained activation of ERK2
can downregulate p21, resulting in cell cycle progression
[28]. We therefore suggest that the significant increase ob-
served in ERK expression after DXR treatment (Fig. 3a),
contributed to the reduction in p21 expression (Fig. 4a).
MCM2 is a marker of proliferation and plays an essen-
tial role in DNA replication [29]. The increase in MCM2
expression observed after DXR treatment indicated that
cell cycle arrest did not occur and that the cancer cells
were actively proliferating (Fig. 3a). This increase in
proliferation supports the increased tumour growth
observed in both low and high doses of DXR.
It has been suggested that EMT can also promote
chemo-resistance in breast cancer tumours [18, 30].
Since we did not observe any significant changes in the
expression levels of the cell surface protein, E-cadherin,
the cytoskeletal proteins, such as α-SMA and Vimentin,
and the transcription factor, Snail, we propose that EMT
did not contribute to the DXR-resistance and tumour
growth observed in our study (Fig. 5).
Conclusions
In conclusion, our results suggest that DXR-induced
drug resistance and tumour growth can occur through
the adaptive role of the MAPK/ERK pathway in an effort
to protect tumour cells. Previous studies have shown
that the efficacy of doxorubicin can be improved by
inhibition of the ERK signalling pathway and thereby
treatment failure can be overcome [6, 24–26].
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